









Markets
/
Stocks
/
nasdaq-fdmt
/

4D Molecular Therapeutics Inc

FDMT

View Detailed Chart

6.420USD

+1.920+42.67%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

297.40MMarket Cap

LossP/E TTM



4D Molecular Therapeutics Inc

6.420

+1.920+42.67%

Overview Company Financials

Financials

Intraday

30m

Today

+42.67%

5 Days

+40.48%

1 Month

+51.42%

6 Months

+8.26%

Year to Date

+15.26%

1 Year

-60.10%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 11 analysts

BUY

Current Rating

29.556

Target Price

360.37%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

4D Molecular Therapeutics Inc

FDMT

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(1)

Neutral(0)

Buy(10)

Indicators

Sell(1)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.229

Buy

RSI(14)

78.111

Buy

STOCH(KDJ)(9,3,3)

69.809

Buy

ATR(14)

0.404

High Vlolatility

CCI(14)

389.460

Overbought

Williams %R

10.465

Overbought

TRIX(12,20)

0.584

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

4.866

Buy

MA10

4.696

Buy

MA20

4.478

Buy

MA50

4.191

Buy

MA100

3.781

Buy

MA200

5.093

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.

Ticker SymbolFDMT

Company4D Molecular Therapeutics Inc

CEODr. David Kirn, M.D.

Websitehttps://4dmoleculartherapeutics.com/